Bio-Techne Corp (TECH) Given Media Impact Rating of 0.57
Media headlines about Bio-Techne Corp (NASDAQ:TECH) have been trending very positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Techne Corp earned a media sentiment score of 0.57 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Expect Bio-Techne Corp (NASDAQ:TECH) Will Post Quarterly Sales of $149.49 Million (americanbankingnews.com)
- Bio-Techne Corp (TECH) Downgraded by BidaskClub (americanbankingnews.com)
- Evolution of new therapies is estimated to provide new opportunities for the growth of the stem cell assay market according to new research report (whatech.com)
- CyberArk Software (CYBR) Q2 Earnings: Likely to Disappoint? (mrtopstep.com)
- Should You Buy Bio-Techne (TECH) Ahead of Earnings? (zacks.com)
Bio-Techne Corp (NASDAQ TECH) traded up 0.77% on Monday, reaching $116.23. 146,798 shares of the company traded hands. Bio-Techne Corp has a 1-year low of $95.68 and a 1-year high of $119.98. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of 62.52 and a beta of 0.79. The stock’s 50-day moving average is $115.98 and its 200-day moving average is $108.12.
Several equities research analysts have commented on TECH shares. TheStreet upgraded shares of Bio-Techne Corp from a “c+” rating to a “b” rating in a research note on Tuesday, May 2nd. Deutsche Bank AG reiterated a “buy” rating and issued a $122.00 price objective (up previously from $115.00) on shares of Bio-Techne Corp in a research note on Wednesday, May 3rd. Citigroup Inc. reissued a “buy” rating and set a $125.00 target price (up from $115.00) on shares of Bio-Techne Corp in a research report on Wednesday, May 3rd. Zacks Investment Research raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a research report on Thursday, July 6th. Finally, BidaskClub raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $123.20.
ILLEGAL ACTIVITY WARNING: “Bio-Techne Corp (TECH) Given Media Impact Rating of 0.57” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/07/bio-techne-corp-tech-earning-very-positive-news-coverage-report-finds-updated-updated-updated.html.
In other news, Director Charles A. Dinarello sold 5,000 shares of Bio-Techne Corp stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $111.37, for a total transaction of $556,850.00. Following the completion of the transaction, the director now directly owns 12,473 shares of the company’s stock, valued at approximately $1,389,118.01. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 10,300 shares of company stock valued at $1,146,707. Insiders own 2.70% of the company’s stock.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.